Dr. Bruce Carleton (PharmD) is Director of the Pharmaceutical Outcomes Programme at BC Children’s Hospital, which is devoted to evaluating the impact of drug therapy on patients’ health outcomes. He is Professor and Chair of the Division of Translational Therapeutics in the Department of Pediatrics, Faculty of Medicine, University of British Columbia (UBC). He is also a Senior Clinician Scientist at the BC Children’s Hospital Research Institute and runs the Canadian Pharmacogenomics Network for Drug Safety, a Canadian and International Network devote to the study of the pharmacogenomic basis of serious adverse drug reactions. He holds faculty appointments at UBC in the Department of Medical Genetics, School of Population and Public Health, Centre for Health Services and Policy Research and the Faculty of Pharmaceutical Sciences. He is also an adjunct professor at the School of Health Information Science at University of Victoria. Dr. Carleton served on the national Canadian Drug Expert Advisory Committee since its inception and serves the United States Government as a Special Government Employee to advise the Advisory Committee for Pharmaceuticals and Clinical Pharmacology of the Food and Drug Administration. A key element of Dr. Carleton's research is the creation of tools to make drug therapy more optimal and safe for all patients. Another key priority is the communication of results to clinicians, patients, healthcare administrators, and government staff who also hold responsibilities to improve patient care.